Australian Clinical Labs Ltd (AU:ACL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd has announced the cessation of Andrew Mark Rendle Dutton as a director, effective from October 25, 2024. Dutton holds 81,897 ordinary shares through Snazfam Pty Limited as part of his superannuation fund. This change in leadership may interest investors monitoring the company’s governance and its potential impact on share value.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.